ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Hemispherx Announces Study that Advances Chronic Fatigue Syndrome (CFS) Programs in Europe

  [ 28 votes ]   [ Discuss This Article ]
By Hemispherx Biopharma, Inc. • www.ProHealth.com • February 11, 2000


PHILADELPHIA, Feb. 11 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) announced that results published today in a leading medical journal show a new one-step diagnostic test for Chronic Fatigue Syndrome (CFS) in European programs has accurately identified this debilitating condition in patients, which may thereby accelerate the overall process of effective therapeutic intervention.

The breakthrough results, published in the peer-reviewed medical journal, "American Journal of Medicine," are part of a study by leading researchers in France and Belgium who are members of the Scientific Advisory Committee for Hemispherx Europe. The researchers evaluated more than 100 patients with different disorders under "blinded conditions" and found that a new biological marker, which was targeted to CFS, was not evident in patients with other fatiguing conditions such as fibromyalgia or depression.

CFS is a chronic debilitating condition characterized by disabling fatigue, fever, myalgia and neurocognitive disturbances. Because a new diagnostic test can identify CFS in patients, therapeutic intervention can take place much more quickly. In fact, certain patients in this study who were diagnosed with CFS using this new test received Ampligen(R), a new product for which Hemispherx Europe has pending marketing applications in 15 European countries.

In related developments, Hemispherx said that the European Parliament recently passed new laws which will accelerate the availability of specific treatments for CFS, and EU member nations, including Italy and Belgium, are actively taking new official regulatory steps to facilitate reimbursement of new medications, which may potentially interrupt the natural history and devastating societal impact of untreated CFS.

Hemispherx Biopharma, which is based in Philadelphia, is a pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including CFS, HIV and hepatitis. Its flagship products are Ampligen(R), which is being developed for CFS and drug-resistant HIV, and polyadenur, which is being developed for hepatitis B and C.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements.

Contact: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc., 215-988-0080; or Mark Kollar of Broadgate Consultants, 212-232-2222, fax, 212-232-3232; or Dianne Will, Investor Relations, 214-954-9300, fax, 214-954-9333



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map